A number of companies and university teams are racing to produce genetic therapies for sickle cell disease. Because the inherited disorder is caused by a single mutation, it’s long been seen as one of the easier potential targets for gene-based treatments, and the advent of CRISPR gene-editing technology has energized the pursuit.
About the Author Reprints
